|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | |||||||||||
| Research and development supplies and other current assets | |||||||||||
| Prepaid expenses | |||||||||||
| Other current assets | |||||||||||
| Total current assets | |||||||||||
| Property and equipment, net | |||||||||||
| Operating lease right-of-use asset, net | |||||||||||
| Other assets | |||||||||||
| Total assets | |||||||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable and accrued expenses | |||||||||||
| Parent company payable | |||||||||||
| Operating lease liability, short-term | |||||||||||
| GEM commitment fee payable | |||||||||||
| Forward contract liability | |||||||||||
| Liability instrument | |||||||||||
| Convertible notes payable, net of debt discount | |||||||||||
| Warrant liability | |||||||||||
| Loan payable | |||||||||||
| SEPA put option liability | |||||||||||
| Short-term convertible debt | |||||||||||
| Total current liabilities | |||||||||||
| Operating lease liability, long-term | |||||||||||
| Total liabilities | |||||||||||
| Stockholders’ equity | |||||||||||
| Preferred Stock, value | |||||||||||
| Series C Preferred Stock | |||||||||||
| Total preferred Stock, value | |||||||||||
| Voting Common Stock, $0.00001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,080,560 shares and 3,325,986 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | |||||||||||
| Nonvoting Common Stock | |||||||||||
| Total voting Common Stock, $0.00001 par value; 300,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 6,080,560 shares and 3,325,986 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Total stockholders’ equity | |||||||||||
| Total liabilities and stockholders’ equity |
Loading...
